Registered title, quoted from ClinicalTrials.gov
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Henan Cancer Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06860529, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 1
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (1 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06860529, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
3.1 Inclusion Criteria
Patients must meet all of the following criteria to be eligible:
Age: ≥18 years old.
Clinical-pathological confirmation:
cT2-cT4 breast cancer, or cT1c with axillary lymph node metastasis.
Histopathologically confirmed HR+/HER2- invasive breast cancer:
ER and/or PR positive (IHC nuclear staining ≥1%).
HER2-negative (IHC 0 or 1+ without FISH testing, or IHC 2+ with FISH-negative amplification).
Ki67 ≥20%.
Clinically measurable lesions:
Measurable lesions confirmed by ultrasound, mammography, or MRI (optional) within 1 month prior to randomization.
Adequate organ and bone marrow function (within 1 month prior to chemotherapy):
Absolute neutrophil count (ANC) ≥2.0 × 10\^9/L.
Hemoglobin ≥90 g/L.
Platelet count ≥100 × 10\^9/L.
Total bilirubin <1.5 × ULN (upper limit of normal).
Creatinine <1.5 × ULN.
AST/ALT <1.5 × ULN.
Cardiac function: Left ventricular ejection fraction (LVEF) ≥55% by echocardiography.
Reproductive status: Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization.
ECOG performance status: ≤1.
Informed consent: Signed written informed consent.
3.2 Exclusion Criteria
Patients meeting any of the following criteria will be excluded:
Evidence of metastatic breast cancer:
Chest/abdominal CT and bone scan required at any time from diagnosis to randomization to exclude metastasis.
PET/CT may substitute for other imaging modalities.
Prior systemic therapy: Chemotherapy, endocrine therapy, targeted therapy, or radiotherapy for the current breast cancer.
Second primary malignancy, except:
Adequately treated non-melanoma skin cancer.
Prior immunotherapy: Treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or other immune checkpoint inhibitors.
Immune-related conditions:
Diagnosed immunodeficiency or active autoimmune disease.
Severe cardiopulmonary disease: Uncontrolled or clinically significant.
Active hepatitis: Hepatitis B or C with detectable viral load.
Transplant history: Prior organ or bone marrow transplantation.
Pregnancy or lactation: Pregnant or breastfeeding women.
Other contraindications: Severe uncontrolled comorbidities deemed by investigators to contraindicate chemotherapy or PD-1 inhibitor therapy.
Quoted from ClinicalTrials.gov, NCT06860529, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06860529, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.